Merck KGaA and its partner Pfizer Inc have stopped a Phase 3 trial of a new drug combination for treatment-naïve patients with locally advanced or metastatic ovarian cancer. The trial was evaluating the immunotherapy avelumab in combination with chemotherapy, followed by maintenance therapy consisting of avelumab in combination with talazoparib, a poly ADP-ribose-polymerase (PARP) inhibitor.
